Deucravacitinib is an tyrosine protein kinase 2 (TYK2) inhibitor to downregulate the IL-23/Th17 and type I interferon pathway, which has been approved by the Food and Drug Administration for oral therapy of psoriasis (14–16). The gene discussed is TYK2; the disease is psoriasis.